NCT00077909 Study of Lung Proteins in Patients With Pneumonia
| NCT ID | NCT00077909 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institutes of Health Clinical Center (CC) |
| Condition | Pneumonia |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2004-02-20 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2004-02-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed by lung x-rays and listening to the chest with a stethoscope. This method can diagnose pneumonia, but it does not provide information on the cause of the inflammation - information that might be helpful in guiding treatment. This study will measure proteins in the lungs of patients to see if certain proteins are associated with specific forms of pneumonia, and can thus serve as biomarkers for disease. Patients undergoing diagnostic bronchoscopy at the NIH Clinical Center may participate in this study. Patients will undergo bronchoscopy and bronchoalveolar lavage as scheduled for their medical care. For this procedure, the patient's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully. Saline (salt water) is then injected through the bronchoscope into the air passage, acting as a rinse. A sample of fluid is then withdrawn for microscopic examination. Researchers in the current study will use some of the fluid obtained from the lavage to examine for protein content. In addition to the bronchoscopy and bronchoalveolar lavage, participants will have about 2 tablespoons of blood drawn to compare blood test results with the results of the lung washings. Patients' medical records will be reviewed to obtain information on past medical history, current medical treatment, vital signs, and results of x-ray tests.
Eligibility Criteria
* INCLUSION CRITERIA: * All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study. * A parent/guardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent. EXCLUSION CRITERIA: Patients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.
Contact & Investigator
Anthony F Suffredini, M.D.
PRINCIPAL INVESTIGATOR
National Institutes of Health Clinical Center (CC)
Frequently Asked Questions
Who can join the NCT00077909 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 99 Years, studying Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00077909 currently recruiting?
Yes, NCT00077909 is actively recruiting participants. Contact the research team at pastorg@cc.nih.gov for enrollment information.
Where is the NCT00077909 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00077909 clinical trial?
NCT00077909 is sponsored by National Institutes of Health Clinical Center (CC). The principal investigator is Anthony F Suffredini, M.D. at National Institutes of Health Clinical Center (CC). The trial plans to enroll 750 participants.